«Poor
responding gynecologic cancers get boost from genomic profiling.»
Not exact matches
An oral
cancer drug improves outcomes while minimizing side effects in women with
gynecologic cancers who carry a BRCA mutation and whose disease is not
responding to other therapies, suggests preliminary research.
As part of an ongoing clinical trial at Rutgers
Cancer Institute exploring rare and poor prognosis
cancers, investigators sought to identify genomic alterations in 69 patients with
gynecologic cancers that were not
responding to standard care.
Research from Rutgers
Cancer Institute of New Jersey examining
gynecologic cancers that poorly
respond to therapy shows genomic profiling can help identify alternate and targeted treatments.